PM534, an Optimized Target-Protein Interaction Strategy through the Colchicine Site of Tubulin

Area of Science:

• Pharmacology
• Oncology
• Marine Natural Products Chemistry

Background:

• Microtubule targeting agents are crucial in chemotherapy but face challenges like neurotoxicity and drug resistance.
• Natural products offer a rich source for novel therapeutic compounds, exemplified by PM742 from the Discodermia sponge.

Purpose of the Study:

• To develop a novel synthetic compound, PM534, with enhanced antitumoral activity and improved resistance profiles.
• To evaluate the efficacy of PM534 against cancer cells and in preclinical tumor models.

Main Methods:

• Structure-Activity-Relationship (SAR) study of natural product PM742 to synthesize PM534.
• In vitro assays to assess tubulin binding affinity and cellular activity, including resistance mechanisms.
• In vivo studies using mouse xenograft models of human non-small cell lung cancer.

Main Results:

• PM534 exhibits nanomolar affinity for the colchicine binding domain of tubulin.
• The compound demonstrates potent antitumor activity, overcoming cellular resistance via detoxification pumps and tubulin βIII isotype overexpression.
• Significant inhibition of tumor growth was observed in non-small cell lung cancer xenograft models.

Conclusions:

• PM534 is a highly effective novel antitumoral compound with a broad spectrum of activity.
• Its ability to overcome key resistance mechanisms makes it a promising candidate for cancer therapy.
• PM534 is currently undergoing Phase I clinical trials, indicating its therapeutic potential.